NeuBase Therapeutics, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q2 2014 to Q4 2022

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
NeuBase Therapeutics, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q2 2014 to Q4 2022.
  • NeuBase Therapeutics, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending December 31, 2022 was $150K.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Period Value YoY Chg Change % Date Report Filed
Q4 2022 $150K Dec 31, 2022 10-Q 2023-11-09
Q2 2014 $28.5K Jun 30, 2014 10-Q 2014-08-18
* An asterisk sign (*) next to the value indicates that the value is likely invalid.